Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03183570 · ClinicalTrials.gov registry record · Early Phase 1
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT03183570: Completed Early Phase 1 study, sponsored by Stanford University.
NCT03183570 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03183570, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with \[18F\]FP-R01-MG-F2 with PET/CT
Interventions
- DRUG [18F]FP-R01-MG-F2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-11-08 |
| Est. Completion | 2025-01-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03183570
The ClinicalTrials.gov registry entry for NCT03183570 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]FP-R01-MG-F2 is the first listed.
NCT03183570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03183570 about?
NCT03183570 is a clinical study titled "Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT". Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with \[18F\]FP-R01-MG-F2 with PET/CT
What is the current status of trial NCT03183570?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2017-11-08. Estimated completion is 2025-01-25.
What interventions are being tested in trial NCT03183570?
The interventions under investigation include: [18F]FP-R01-MG-F2 (DRUG).
Who is sponsoring clinical trial NCT03183570?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.